+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis



Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis



Expert Opinion on Biological Therapy 16(6): 827-839



Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058704795

Download citation: RISBibTeXText

PMID: 26914737

DOI: 10.1517/14712598.2016.1158809


Related references

Recent advances in multiple sclerosis therapies. Inflammation Research 50(Supplement 3): S153, 2001

Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12(4): 171-178, 2006

An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20(2): 167-180, 2007

Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1(1): 43-52, 2008

Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. Expert Review of Neurotherapeutics 2019: 1-13, 2019

Stem cell-based therapies for multiple sclerosis: recent advances in animal models and human clinical trials. Regenerative Medicine 9(2): 129-132, 2015

Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Therapeutic Advances in Neurological Disorders 8(6): 274-293, 2015

Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. Multiple Sclerosis and Related Disorders 25: 322-328, 2018

Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis. Noro Psikiyatri Arsivi 55(Suppl 1): S15-S20, 2019

Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada. Reviews in Neurological Diseases 2(1): 23-26, 2006

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis 21(7): 885-893, 2016

Recent advances on pathogenesis and therapies in systemic sclerosis. Clinical Reviews in Allergy and Immunology 33(1-2): 107-112, 2007

Advances in the management of psoriasis: monoclonal antibody therapies. International Journal of Dermatology 41(12): 827-835, 2002

Amyotrophic lateral sclerosis: recent advances and future therapies. Current Opinion in Neurology 18(6): 712-719, 2005

Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacology and Therapeutics 138(3): 452-469, 2013